Rational design of cancer-drug combinations.
Ramaswamy
Sridhar
S
Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D015195:Drug Design; D005804:Genes, Lethal; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D017239:Paclitaxel / Q000008:administration & dosage*; D034622:RNA Interference; D034741:RNA, Small Interfering
D000970:Antineoplastic Agents; D034741:RNA, Small Interfering; D017239:Paclitaxel